New-onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination: A case report.
J Diabetes Investig
; 13(7): 1286-1289, 2022 Jul.
Article
in English
| MEDLINE | ID: covidwho-1853865
ABSTRACT
Fulminant type 1 diabetes is characterized by a rapid progression of insulin deficiency triggered by viral infection. Here, we report a case of a 45-year-old Japanese woman with fulminant type 1 diabetes that developed 8 days after receiving messenger ribonucleic acid vaccine against severe acute respiratory syndrome coronavirus 2. She had been healthy and had no symptoms suggestive of viral infection before the vaccination. Laboratory tests showed exhaustion of insulin secretion and negative results for islet autoantibodies. Human leukocyte antigen genotype analysis showed the DRB1*0405 and DQB1*0401 alleles. This is the first case report of new-onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination, and suggests that a severe acute respiratory syndrome coronavirus 2 vaccine might trigger the onset of fulminant type 1 diabetes in susceptible individuals. However, a causal relationship remains to be identified, and further studies are required to determine the incidence of such cases.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Diabetes Mellitus, Type 1
/
COVID-19
Type of study:
Case report
/
Diagnostic study
/
Observational study
Topics:
Long Covid
/
Vaccines
Limits:
Female
/
Humans
/
Middle aged
Language:
English
Journal:
J Diabetes Investig
Year:
2022
Document Type:
Article
Affiliation country:
Jdi.13771
Similar
MEDLINE
...
LILACS
LIS